These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33864386)

  • 1. Olinciguat, a stimulator of soluble guanylyl cyclase, attenuates inflammation, vaso-occlusion and nephropathy in mouse models of sickle cell disease.
    Tchernychev B; Li H; Lee SK; Gao X; Ramanarasimhaiah R; Liu G; Hall KC; Bernier SG; Jones JE; Feil S; Feil R; Buys ES; Graul RM; Frenette PS; Masferrer JL
    Br J Pharmacol; 2021 Sep; 178(17):3463-3475. PubMed ID: 33864386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial Effects of Soluble Guanylyl Cyclase Stimulation and Activation in Sickle Cell Disease Are Amplified by Hydroxyurea: In Vitro and In Vivo Studies.
    Ferreira WA; Chweih H; Lanaro C; Almeida CB; Brito PL; Gotardo EMF; Torres L; Miguel LI; Franco-Penteado CF; Leonardo FC; Garcia F; Saad STO; Frenette PS; Brockschnieder D; Costa FF; Stasch JP; Sandner P; Conran N
    J Pharmacol Exp Ther; 2020 Sep; 374(3):469-478. PubMed ID: 32631869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olinciguat, an Oral sGC Stimulator, Exhibits Diverse Pharmacology Across Preclinical Models of Cardiovascular, Metabolic, Renal, and Inflammatory Disease.
    Zimmer DP; Shea CM; Tobin JV; Tchernychev B; Germano P; Sykes K; Banijamali AR; Jacobson S; Bernier SG; Sarno R; Carvalho A; Chien YT; Graul R; Buys ES; Jones JE; Wakefield JD; Price GM; Chickering JG; Milne GT; Currie MG; Masferrer JL
    Front Pharmacol; 2020; 11():419. PubMed ID: 32322204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitric Oxide-Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease.
    Potoka KP; Wood KC; Baust JJ; Bueno M; Hahn SA; Vanderpool RR; Bachman T; Mallampalli GM; Osei-Hwedieh DO; Schrott V; Sun B; Bullock GC; Becker-Pelster EM; Wittwer M; Stampfuss J; Mathar I; Stasch JP; Truebel H; Sandner P; Mora AL; Straub AC; Gladwin MT
    Am J Respir Cell Mol Biol; 2018 May; 58(5):636-647. PubMed ID: 29268036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice.
    Almeida CB; Scheiermann C; Jang JE; Prophete C; Costa FF; Conran N; Frenette PS
    Blood; 2012 Oct; 120(14):2879-88. PubMed ID: 22833547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral carbon monoxide therapy in murine sickle cell disease: Beneficial effects on vaso-occlusion, inflammation and anemia.
    Belcher JD; Gomperts E; Nguyen J; Chen C; Abdulla F; Kiser ZM; Gallo D; Levy H; Otterbein LE; Vercellotti GM
    PLoS One; 2018; 13(10):e0205194. PubMed ID: 30308028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The fucosylation inhibitor, 2-fluorofucose, inhibits vaso-occlusion, leukocyte-endothelium interactions and NF-ĸB activation in transgenic sickle mice.
    Belcher JD; Chen C; Nguyen J; Abdulla F; Nguyen P; Nguyen M; Okeley NM; Benjamin DR; Senter PD; Vercellotti GM
    PLoS One; 2015; 10(2):e0117772. PubMed ID: 25706118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MASP-2 and MASP-3 inhibitors block complement activation, inflammation, and microvascular stasis in a murine model of vaso-occlusion in sickle cell disease.
    Belcher JD; Nguyen J; Chen C; Abdulla F; Conglin R; Ivy ZK; Cummings J; Dudler T; Vercellotti GM
    Transl Res; 2022 Nov; 249():1-12. PubMed ID: 35878790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CNS-penetrant soluble guanylate cyclase stimulator CYR119 attenuates markers of inflammation in the central nervous system.
    Correia SS; Liu G; Jacobson S; Bernier SG; Tobin JV; Schwartzkopf CD; Atwater E; Lonie E; Rivers S; Carvalho A; Germano P; Tang K; Iyengar RR; Currie MG; Hadcock JR; Winrow CJ; Jones JE
    J Neuroinflammation; 2021 Sep; 18(1):213. PubMed ID: 34537066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patrolling monocytes scavenge endothelial-adherent sickle RBCs: a novel mechanism of inhibition of vaso-occlusion in SCD.
    Liu Y; Zhong H; Bao W; Mendelson A; An X; Shi P; Chou ST; Manwani D; Yazdanbakhsh K
    Blood; 2019 Aug; 134(7):579-590. PubMed ID: 31076443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TGF-β1 Reduces Neutrophil Adhesion and Prevents Acute Vaso-Occlusive Processes in Sickle Cell Disease Mice.
    Torres LS; Chweih H; Fabris FCZ; Gotardo EMF; Leonardo FC; Saad STO; Costa FF; Conran N
    Cells; 2022 Apr; 11(7):. PubMed ID: 35406764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impairment of Nitric Oxide Pathway by Intravascular Hemolysis Plays a Major Role in Mice Esophageal Hypercontractility: Reversion by Soluble Guanylyl Cyclase Stimulator.
    Henrique Silva F; Yotsumoto Fertrin K; Costa Alexandre E; Beraldi Calmasini F; Fernanda Franco-Penteado C; Ferreira Costa F
    J Pharmacol Exp Ther; 2018 Nov; 367(2):194-202. PubMed ID: 30108160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease.
    Belcher JD; Chen C; Nguyen J; Milbauer L; Abdulla F; Alayash AI; Smith A; Nath KA; Hebbel RP; Vercellotti GM
    Blood; 2014 Jan; 123(3):377-90. PubMed ID: 24277079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelial TLR4 Expression Mediates Vaso-Occlusive Crisis in Sickle Cell Disease.
    Beckman JD; Abdullah F; Chen C; Kirchner R; Rivera-Rodriguez D; Kiser ZM; Nguyen A; Zhang P; Nguyen J; Hebbel RP; Belcher JD; Vercellotti GM
    Front Immunol; 2020; 11():613278. PubMed ID: 33542720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure.
    Shea CM; Price GM; Liu G; Sarno R; Buys ES; Currie MG; Masferrer JL
    Am J Physiol Renal Physiol; 2020 Jan; 318(1):F148-F159. PubMed ID: 31608671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. cGMP modulation therapeutics for sickle cell disease.
    Conran N; Torres L
    Exp Biol Med (Maywood); 2019 Feb; 244(2):132-146. PubMed ID: 30691292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of placental growth factor reduces vaso-occlusive complications in murine models of sickle cell disease.
    Gu JM; Yuan S; Sim D; Abe K; Liu P; Rosenbruch M; Bringmann P; Kauser K
    Exp Hematol; 2018 Apr; 60():73-82.e3. PubMed ID: 29337222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea with AKT2 inhibition decreases vaso-occlusive events in sickle cell disease mice.
    Barazia A; Li J; Kim K; Shabrani N; Cho J
    Blood; 2015 Nov; 126(22):2511-7. PubMed ID: 26265698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state.
    Sins JWR; Schimmel M; Luken BM; Nur E; Zeerleder SS; van Tuijn CFJ; Brandjes DPM; Kopatz WF; Urbanus RT; Meijers JCM; Biemond BJ; Fijnvandraat K
    J Thromb Haemost; 2017 Jul; 15(7):1392-1402. PubMed ID: 28457019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High molecular weight kininogen contributes to early mortality and kidney dysfunction in a mouse model of sickle cell disease.
    Sparkenbaugh EM; Kasztan M; Henderson MW; Ellsworth P; Davis PR; Wilson KJ; Reeves B; Key NS; Strickland S; McCrae K; Pollock DM; Pawlinski R
    J Thromb Haemost; 2020 Sep; 18(9):2329-2340. PubMed ID: 32573897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.